文献速递白血病

尼洛替尼联合干扰素-α治疗慢性髓性白血病患者的免疫调节研究

Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
PubMed 文献 · Br J Haematol · 2023-07-22

在ALLG CML11试验中,对接受尼洛替尼联合干扰素-α治疗(n=12)或尼洛替尼单药治疗(n=17)的慢性期慢性髓性白血病患者进行纵向免疫学评估。联合治疗短暂降低NK细胞绝对计数及CD16+细胞毒性和CD57+CD62L-成熟NK细胞,但不影响NK细胞功能;干扰素短暂增加针对白血病相关抗原的CTL反应,对调节性T细胞和髓源性抑制细胞无影响。12个月时达到MR4.5的患者NK细胞表达NKp46、NKp30和NKG2D的比例显著更高,该差异在尼洛替尼单药组未观察到。

要点

  • 尼洛替尼联合干扰素-α短暂降低NK细胞绝对计数,但不影响NK细胞功能。
  • 干扰素短暂增加针对蛋白酶3、BMI-1和PRAME的细胞毒性T淋巴细胞反应。
  • 12个月达到MR4.5者NK细胞表达NKp46、NKp30和NKG2D比例显著更高。

核心结论

  • 尼洛替尼联合干扰素-α驱动NK活化受体增加和针对白血病相关抗原的CTL反应,产生短暂免疫调节,可能影响早期深度分子学缓解,其对长期结局的影响值得进一步研究。

研究设计与样本

  • 在ALLG CML11试验中,对接受尼洛替尼联合干扰素-α治疗的慢性期慢性髓性白血病患者(n=12)或尼洛替尼单药治疗的患者(n=17)进行纵向免疫学评估。

主要发现

  • 与尼洛替尼单药相比,尼洛替尼联合干扰素短暂降低自然杀伤(NK)细胞绝对计数。
  • 干扰素治疗期间CD16+细胞毒性NK细胞和CD57+CD62L-成熟NK细胞短暂降低,但不影响NK细胞功能。
  • 干扰素短暂增加针对白血病相关抗原蛋白酶3、BMI-1和PRAME的细胞毒性T淋巴细胞(CTL)反应,对调节性T细胞或髓源性抑制细胞无影响。
  • 12个月时达到MR4.5的尼洛替尼联合干扰素患者,其NK细胞表达NKp46、NKp30和NKG2D的比例显著高于未达到该里程碑的患者,该差异在尼洛替尼单药组未观察到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出干扰素联合尼洛替尼对长期结局的影响值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The addition of interferon to tyrosine kinase inhibitors (TKIs), to improve deep molecular response (DMR) and potentially treatment-free remission (TFR) rates in chronic-phase chronic myeloid leukaemia (CP-CML) patients is under active investigation. However, the immunobiology of this combination is poorly understood. We performed a comprehensive longitudinal assessment of immunological changes in CML patients treated with nilotinib and interferon-alpha (IFN-α) within the ALLG CML11 trial (n = 12) or nilotinib alone (n = 17). We demonstrate that nilotinib+IFN transiently reduced absolute counts of natural killer (NK) cells, compared with nilotinib alone. Furthermore, CD16+ -cytolytic and CD57+ CD62L- -mature NK cells were transiently reduced during IFN therapy, without affecting NK-cell function. IFN transiently increased cytotoxic T-lymphocyte (CTL) responses to leukaemia-associated antigens (LAAs) proteinase-3, BMI-1 and PRAME; and had no effect on regulatory T cells, or myeloid-derived suppressor cells. Patients on nilotinib+IFN who achieved MR4.5 by 12 months had a significantly higher proportion of NK cells expressing NKp46, NKp30 and NKG2D compared with patients not achieving this milestone. This difference was not observed in the nilotinib-alone group. The addition of IFN to nilotinib drives an increase in NK-activating receptors, CTLs responding to LAAs and results in transient immune modulation, which may influence earlier DMR, and its effect on long-term outcomes warrants further investigation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Irani YD, Hughes A, Kok CH, et al. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. Br J Haematol. 2023. PMID: 37482935. doi:10.1111/bjh.18984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。